Adult Cardiac Stem Cell Isolation via SOX17 and GATA4 Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cardiac stem cell therapies face challenges due to immunogenic rejection and the propensity to form teratomas, limiting their therapeutic application, and existing stem cell lines often cause immune responses and have limited expansion capabilities.
Innovation Solution
Isolation and expansion of adult cardiac stem cells expressing specific markers such as SOX17, GATA4, IL-1β, and CD31, while lacking markers like Oct4, Nanog, and telomerase reverse transcriptase, which allows for differentiation into adipocytes, osteocytes, endothelial cells, and smooth muscle cells, reducing immunogenicity and tumorigenic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adult cardiac stem cells are used for therapeutic applications, then tissue regeneration capability is improved, but immunogenic rejection occurs
Solution Approach 1:
The patent applies parameter changes by selecting and characterizing stem cells based on specific marker expression profiles (SOX17+, GATA4+, IL-1β+, CD31+; Oct4-, Nanog-, c-kit-). This parameter-based selection identifies a subset of cardiac stem cells with reduced immunogenicity while maintaining regenerative capacity, thereby resolving the contradiction between therapeutic effectiveness and immune rejection
2Adaptability or versatility
If adult-derived multipotent cells are used, then differentiation capability is improved, but teratoma formation occurs
Solution Approach 1:
The patent uses parameter changes by defining specific marker expression patterns to identify cardiac stem cells that have differentiated commitment while retaining multipotency. The selected cells express markers indicating cardiac lineage commitment (SOX17, GATA4) but lack pluripotency markers (Oct4, Nanog), thereby achieving differentiation capability without teratoma risk
Solution Approach 2:
The patent applies the extraction principle by isolating and selecting a specific subset of cardiac stem cells with particular marker profiles from the broader population of adult stem cells. This extraction identifies cells that have lost pluripotency markers (Oct4, Nanog, c-kit) while maintaining cardiac-specific markers, thereby separating the desired differentiation capability from the harmful teratoma-forming potential
3Quantity of substance
If existing cardiac stem cell lines are expanded, then cell population size is improved, but limited expansion capability is observed
Solution Approach 1:
The patent applies parameter changes by identifying and selecting cardiac stem cells based on specific marker expression patterns that correlate with enhanced expansion potential. The selected cell population (SOX17+, GATA4+, IL-1β+, CD31+; Oct4-, Nanog-, c-kit-) demonstrates improved proliferative capacity and expansion capability compared to previously described cardiac stem cell lines
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to the identification, isolation, expansion and characterization of a specific type of multipotentadult cardiac stem cell. These adult stem cells are characterised in that they naturally express a specific pattern of markers, which can be used to assist with their isolation and expansion. In particular, the cells express SOX17 and GATA4, but do not express Oct4, Nanog, c-kitand telomerase reverse transcriptase. These cells areable to differentiate into one or more of the following cell types: adipocytes, osteocytes, endothelial cells and/or smooth muscle cells. They also display an unprecedented capacity for immunoregulation as well as providing, activating and/or inducing repair of damaged cardiac tissue. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium.